Needle-less to say, it’s effective!

Eli Lilly’s experimental GLP-1 pill caused participants in a late-stage trial to shed an average of 10.5% of their body weight — nearly 23 pounds — over 16 months, according to data released Tuesday .

The daily medication, known as orforglipron, has also been shown to reduce hemoglobin A1C —average blood sugar levels over the past two to three months — by 1.3% to 1.8% in people with diabetes. 3

Lilly plans to submit its full trial data for US regulatory approval for obesity by the end of the year, which would reshape a GLP-1 market dominated by injectables.

“If approved, we are ready to offer a convenient, once-daily pill that can be scaled globally — removing barriers and redefining how obesity is treated around the world,” Kenneth Custer, L

See Full Page